|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,543.90 INR | +2.35% |
|
+2.45% | +0.70% |
| 06-02 | Alkem Laboratories Limited Launches Semaglutide in Single-Shot Pre-Filled Syringes At Price Starting Inr 350 | CI |
| 06-02 | Alkem Laboratories Shows Strong Moves But Weak Follow-Through |
Company Valuation: Alkem Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 331,171 | 432,909 | 406,055 | 590,890 | 583,680 | 647,624 | - | - |
| Change | - | 30.72% | -6.2% | 45.52% | -1.22% | 10.96% | - | - |
| Enterprise Value (EV) 1 | 328,603 | 433,805 | 393,853 | 587,236 | 578,678 | 632,481 | 617,149 | 603,569 |
| Change | - | 32.02% | -9.21% | 49.1% | -1.46% | 9.3% | -0.38% | -2.2% |
| P/E | 20.9x | 26.3x | 41.3x | 32.9x | 27x | 27.5x | 27.6x | 24x |
| PBR | 4.49x | 5.01x | 4.49x | 5.73x | 4.87x | 4.58x | 4.19x | 3.7x |
| PEG | - | 6.89x | -1x | 0.4x | 1.3x | 4.37x | -3.79x | 1.6x |
| Capitalization / Revenue | 3.74x | 4.07x | 3.5x | 4.66x | 4.5x | 4.31x | 3.91x | 3.55x |
| EV / Revenue | 3.71x | 4.08x | 3.4x | 4.64x | 4.46x | 4.3x | 3.73x | 3.31x |
| EV / EBITDA | 16.9x | 21.1x | 24.5x | 26.2x | 23x | 21x | 18.1x | 15.5x |
| EV / EBIT | 19.7x | 24.8x | 30.3x | 30.2x | 26.9x | 24.1x | 20.8x | 17.7x |
| EV / FCF | 30.4x | 55.4x | 27.1x | 33.3x | 45.3x | 42.8x | 34.1x | 29x |
| FCF Yield | 3.29% | 1.81% | 3.69% | 3% | 2.21% | 2.33% | 2.94% | 3.45% |
| Dividend per Share 2 | 28 | 34 | 25 | 40 | 45 | 53 | 51.49 | 56.66 |
| Rate of return | 1.01% | 0.94% | 0.74% | 0.81% | 0.92% | 1% | 0.95% | 1.05% |
| EPS 2 | 132.6 | 137.6 | 82.31 | 150.2 | 181.1 | 192.5 | 196 | 225.4 |
| Distribution rate | 21.1% | 24.7% | 30.4% | 26.6% | 24.8% | 27.5% | 26.3% | 25.1% |
| Net sales 1 | 88,650 | 106,342 | 115,993 | 126,676 | 129,645 | 147,123 | 165,551 | 182,526 |
| EBITDA 1 | 19,424 | 20,529 | 16,094 | 22,455 | 25,122 | 30,052 | 34,136 | 38,956 |
| EBIT 1 | 16,678 | 17,490 | 12,990 | 19,462 | 21,550 | 26,232 | 29,663 | 34,038 |
| Net income 1 | 15,850 | 16,456 | 9,842 | 17,958 | 21,655 | 23,018 | 23,923 | 27,679 |
| Net Debt 1 | -2,568 | 896.1 | -12,202 | -3,654 | -5,003 | -1,094 | -30,475 | -44,054 |
| Reference price 2 | 2,769.80 | 3,620.70 | 3,396.10 | 4,942.00 | 4,881.70 | 5,416.50 | 5,416.50 | 5,416.50 |
| Nbr of stocks (in thousands) | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | - | - |
| Announcement Date | 25/05/21 | 13/05/22 | 19/05/23 | 29/05/24 | 29/05/25 | 28/05/26 | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 35.95x | 13.06x | 26.6x | 0.55% | 1,097B | ||
| 27.63x | 6.35x | 17.27x | 2.06% | 622B | ||
| 31.37x | 7.5x | 15.34x | 2.72% | 449B | ||
| 18.05x | 4.48x | 11.03x | 2.96% | 334B | ||
| 23.74x | 4.94x | 14.01x | 1.76% | 294B | ||
| 21.75x | 5.59x | 13.5x | 2.83% | 286B | ||
| 13.9x | 5.17x | 10.63x | 3.6% | 213B | ||
| 23.5x | 6.26x | 11.01x | 2.8% | 195B | ||
| -45.11x | 5.46x | 30.35x | 2.57% | 157B | ||
| Average | 16.75x | 6.53x | 16.64x | 2.43% | 405.19B | |
| Weighted average by Cap. | 24.79x | 8.05x | 18.55x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALKEM Stock
- ALKEM Stock
- Valuation Alkem Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
















